United Therapeutics: Is UTHR Stock Still A Buy At $400?
1. UTHR stock surged 33% after positive IPF trial results. 2. Tyvaso could add $4-5 billion in peak sales if approved. 3. Company exhibits strong fundamentals, viewing UTHR as attractive. 4. UTHR's financial metrics outperform S&P 500 benchmarks significantly. 5. Stock shows resilience during past market downturns.